VECAM - Vecta

Drug Profile

VECAM - Vecta

Alternative Names: Esomeprazole/succinate acid; Omeprazole/succinic acid; PPI/VB101; Proton pump inhibitor/succinic acid; VB101; VB101/PPI; VCT-111; VECAM; Vecam 20/300; Vecam 40/300; VECAM-110; VECAM-111

Latest Information Update: 28 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vecta
  • Class Antiulcers; Small molecules; Succinic acids
  • Mechanism of Action Proton pump inhibitors; Proton pump stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 28 Aug 2015 No recent reports on development identified - Phase-II for Gastro-oesophageal reflux in USA (PO)
  • 30 Jun 2011 Vecta completes a phase IIb trial in Gastro-oesophageal reflux in USA (NCT01059383)
  • 17 Sep 2010 VB 101 is available for licensing as of 30 Jun 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top